Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrogen plus tetrandrine for silicosis fibrosis
ISRCTN12356200Phase 2Completed
- Sponsor
- Laizhou Chronic Disease Prevention and Treatment Hospital
- Start
- Oct 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Molecular hydrogen and tetrandrine in silicosis (2 arms), sponsored by Laizhou Chronic Disease Prevention and Treatment Hospital. Primary endpoint: Diffusion lung capacity for carbon monoxide at 6 months. Started Oct 2023; status: completed.
02
Drugs
Molecular hydrogentetrandrine
03
Conditions
silicosis
Beyond the preview
Go deeper on ISRCTN12356200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12356200.